Exchange: NASDAQ·Updated 07:30 PM EDT
UTHR logo

UTHR United Therapeutics Corp

$549.16
$16.38
(3.07%)
Today
Closed $549.16
$0.00
(0.00%)
After Hours
EarningsOct 28
Mkt Cap$22.85B
Vol577,863.00

About UTHR

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
46

Neutral Sentiment

How do you feel about UTHR?

amsteliam
$UTHR $LQDA $MNKD If you're a LQDA holder, do you wait a week for whatever outcome, or do you GTFO now? I'd be out, but I never bought that shit.
8
kcphaeton
$UTHR $MNKD $LQDA now that Martine has won her big lawsuit. It’s just a matter of time before she focuses on buying Mannkind while it’s cheap. She’s got plenty of cash in the bank. . She can either do it with stock or cash. I would bet she will do it with cash.
2
grampslol
$UTHR back in 2018 before they obtained trep dpi and technosphere from $MNKD for chump change Martine wanted to buy $LQDA will the court case settle with what she wanted all along, full control of $LQDA ? we'll see ...
1
AfrezzaFactsMatter
$UTHR is up nicely. $MNKD tanking as usual. But at least the TUTES can continue to gobble up retail shares according to KukaAi.
1
BTP_Trading
$UTHR thanks for the pump so I could get out with nice little profit! Would consider rebuying if that huge gap gets filled around 320
1
iomete_stulta
$UTHR i like how this board is more full of rando company copium instead of actually being about UTHR lol
1
grampslol
whatever the $UTHR $LQDA verdict may be $MNKD flagship drug, 12 year old + afrezza dpi, is a flop ... pps will be pennyland #factsmatter #afizzle
msgu1021
$UTHR Looks like Wall Street not bullish about She-Man action. She/ he is not getting anything much out of LQDA drama ! Ouch…
Stoxpo
$UTHR - United Therapeutics shares are trading higher after the company confirmed a patent litigation legal judgement in its favor in a claim against Liquidia. Also, BTIG upgraded its rating on the stock from Neutral to Buy and announced a $728 price target. $SNPS - Synopsys shares are trading higher after the company issued FY27 guidance above estimates. $VICR - Vicor shares are trading higher after the company raised its Q3 sequential revenue growth guidance. Also, the company issued Q3 revenue guidance above estimates.
Markad0
$UTHR I know I saw it yesterday, either on this ticker or MNKD's that this would be a market cap swap. At this moment, couldn't get much closer, Lqda down $4.5B, UTHR up by the same (rounding in both cases).
grampslol
Can see $UTHR and $LQDA merging ... what would happen to the afrezza dpi company, $MNKD we mustn't forget that it's flagship is a pharmaceutical flop of epic proportions... #afizzle
KryptonResearch14
$UTHR United Therapeutics' best session in a year was not priced as a win. Leerink's read on the Yutrepia patent ruling: heading in, the investor base case was that UTHR would LOSE the case. The +12.3% to $540.54 was the Street unwinding that expectation, not just cheering the verdict. The share math is the one level down. Yutrepia had been gaining share on Tyvaso each quarter. If the '327 ruling slows or stops that, the Tyvaso trajectory in Street models may be marked too low. Leerink: that upside "was not previously reflected in Street estimates." The read-through already moved: MannKind, UTHR's Tyvaso partner, popped ~17%. Final judgment lands in about a week: label strip, sales injunction, or royalties. That decides whether this is franchise protection or franchise plus income.
cubie
$UTHR $LQDA $GOOGL charts da.bomb. cubie teaches and uthr up 66.6 not that cubie notice or anything 🤭. didnt notice $USO closed down -$6.66 yesterday either🤭
ElectricRefreshments
$UTHR I’ll buy at 400. Might be a long shot but that’s my next watch. Looking to fill the gap
cuttail07
$UTHR Stagnant to mildly declining Tyvaso + Tyvaso DPi quarterly revenues over the past year (in the setting of increased competition). Accelerated share repurchase to try to save face on EPS figures. I’m a believer on a 5-year time horizon here due to TAM expansion from IPF and eventual launch of Ralinepag. But they were no longer reiterating 2026 guidance and PDUFA dates and product/new indication launches not until 2027. Sitting on sidelines with a hope to dollar cost avg into more shares starting at 450.

Advertisement|Remove ads.